References
- Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 2004; 22: 2835–2841
- Brusamolino E, Baio A, Orlandi E, Arcaini L, Passamonti F, Griva V, et al. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up. Clin Cancer Res 2006; 2: 6487–6493
- Connors J M. State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol 2005; 23: 6400–6408
- Diehl V, Brillant D, Engert A, Mueller M, Mueller-Hermelink H, Hermann R, , German Hodgkin Study Group and Competence Network Malignant Lymphoma HD10, et al. Investigating reduction of combined modality treatment intensity in early stage Hodgkin's lymphoma. Interim analysis of a randomized trial of the German Hodgkin Study Group (GHSG). J Clin Oncol, 2005 ASCO Annu Meeting Proc., 23(16S), Part I of II (June 1 Suppl):6506
- Viviani S, Bonfante V, Santoro A, Zanini M, Devizzi L, Di Russo A D, et al. Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease. Cancer J Sci Am 1999; 5: 275–282
- Devizzi L, Santoro A, Bonfante V, Viviani S, Bonadonna G. Vinorelbine: a new promising drug in Hodgkin's disease. Leuk Lymphoma 1996; 22: 409–414
- Connors J M, Klimo P, Adams G, Burns B F, Cooper I, Meyer R M, et al. Treatment of advanced Hodgkin's disease with chemotherapy—comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. J Clin Oncol 1997; 4: 1638–1645
- Sieniawski M, Franklin J, Nogova L, Glossmann J P, Schober T, Nisters-Backes H, et al. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma. J Clin Oncol 2007; 25: 2000–2005
- Lister T A, Crowther D, Sutcliffe S B, Glatstein E, Canellos G P, Young R C, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630–1636
- Cheson B D, Pfistner B, Juweid M E, Gascoyne R D, Specht L, Horning S J, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579–586
- Noordijk E M, Carde P, Dupouy N, Hagenbeek A, Krol A D, Kluin-Nelemans J C, et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 2006; 24: 3128–3135
- Fisher R I, DeVita V T, Hubbard S P, Simon R, Young R C. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Intern Med 1979; 90: 761–763
- Viviani S, Santoro A, Negretti E, Bonfante V, Valagussa P, Bonadonna G. Salvage chemotherapy in Hodgkin's disease. Results in patients relapsing more than twelve months after first complete remission. Ann Oncol 1990; 1: 123–127